Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O75342
UPID:
LX12B_HUMAN
Alternative names:
Epidermis-type lipoxygenase 12
Alternative UPACC:
O75342
Background:
Arachidonate 12-lipoxygenase, 12R-type, also known as Epidermis-type lipoxygenase 12, plays a pivotal role in the synthesis of corneocytes lipid envelope, essential for the skin barrier's integrity against water loss. It catalyzes the incorporation of dioxygen into polyunsaturated fatty acids, leading to lipid hydroperoxides formation, crucial for skin health and mucin expression regulation.
Therapeutic significance:
The protein's involvement in Ichthyosis, congenital, autosomal recessive 2, underscores its therapeutic potential. Understanding the role of Arachidonate 12-lipoxygenase, 12R-type could open doors to potential therapeutic strategies for skin disorders, highlighting the importance of targeted research in uncovering novel treatments.